Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.

ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...

New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...

EPP arises from reduced ferrochelatase activity and excess protoporphyrin made largely in the bone marrow. Accurate diagnosis ...

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

The panel reviews years of efficacy and safety data behind today's approved HS biologics. "Long-Term Efficacy and Safety Data for HS Biologics" takes up the clinical trial evidence behind adalimumab, ...

Baricitinib (Olumiant) is FDA-approved for pediatric patients 12 years of age and older with severe alopecia areata, in ...

September marks Alopecia Areata Awareness Month, providing an opportunity to recognize the experiences of patients living with alopecia areata (AA) while reflecting on continued advances in the ...

Explore what drives male pattern hair loss, its emotional toll, and why new topical antiandrogen clascoterone may boost density while limiting systemic effects. To conclude this Dermatology Times ...

Weekly spot-test format aims to reinforce dermatology fundamentals while integrating evolving evidence and practice patterns.

From new therapeutic data and late-breaking trials to evolving approaches to precision medicine, inflammatory disease, alopecia, and cutaneous oncology, EADV 2026 is positioned to provide a broad look ...

Dermatology Times and NPPA Connect celebrate National APP Week 2026 by highlighting the voices, experiences, and impact of advanced practice providers in dermatology. Across a week of conversations, ...